Exact Sciences - Biotechwert mit großer Hoffnung - 500 Beiträge pro Seite
eröffnet am 23.07.05 15:47:01 von
neuester Beitrag 10.01.06 18:37:42 von
neuester Beitrag 10.01.06 18:37:42 von
Beiträge: 6
ID: 995.178
ID: 995.178
Aufrufe heute: 0
Gesamt: 1.183
Gesamt: 1.183
Aktive User: 0
ISIN: US30063P1057 · WKN: 590273 · Symbol: EXAS
63,53
USD
+1,79 %
+1,12 USD
Letzter Kurs 22:00:00 Nasdaq
Neuigkeiten
15.04.24 · Business Wire (engl.)  |
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes 11.04.24 · Business Wire (engl.) |
08.04.24 · Business Wire (engl.) |
08.04.24 · Business Wire (engl.) |
04.04.24 · Business Wire (engl.) |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5285 | +36,60 | |
| 0,6000 | +25,26 | |
| 4,5800 | +24,46 | |
| 1,8300 | +23,65 | |
| 0,7600 | +21,68 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7008 | -15,56 | |
| 0,7603 | -15,56 | |
| 2,8600 | -19,21 | |
| 27,00 | -49,30 | |
| 3,4200 | -53,53 |
Feedback
Was haltet ihr hiervon? Ich finde besonders bemerkenswert, dass sich knapp 50% der Aktien in Händen von Institutionellen Anlegern befinden
EXAS
EXACT Sciences Corporation NASDAQ-NM
Umsatz 2001: 51.000$
Verlust: 23,4 Mio $
Umsatz 2002: 897.000$
Verlust: 29,9 Mio$
Umsatz 2003: 2,9 Mio$
Verlust: 28,3 Mio$
Umsatz 2004: 4,9 Mio$
Verlust: 18,5 Mio$
Quartal I 05:
Umsatz: 1,25 Mio$
Verlust: 4,5 Mio$
Zahlen für das 2. Quartal kommen am 26.7
MK: 59,8 Mio$ bei aktuellem Kurs 2,28$
Anteil Institutionelle: 49,5%
About EXACT Sciences
EXACT Sciences is an applied genomics company founded in 1995. The Company’s mission is to eradicate mortality from common cancers — starting with colorectal cancer — by applying advances in the field of genomics to facilitate the early detection of disease.
EXACT Sciences’ first target is colorectal cancer, the second leading cause of cancer deaths and the most deadly cancer among non-smoking men and women in the United States. This year, approximately 150,000 people will be diagnosed with colorectal cancer and almost 60,000 people will die from the disease. Of those diagnosed, nearly half are expected to die within five years, since most cancers are detected when the cancer is less treatable. For those whose cancer is detected at an earlier stage, the five-year survival rate can be greater than 90%. The American Cancer Society recommends that all Americans age 50 and older be screened regularly for colorectal cancer. Unfortunately, only a fraction of this population is screened for the disease, as currently available screening technologies are considered by many as either too invasive or inaccurate.
EXACT Sciences believes its non-invasive genomics-based technologies will revolutionize the early detection of colorectal cancer by increasing the number of people who are screened effectively and regularly for colorectal cancer.
PreGen-Plus™ can revolutionize your approach to colorectal cancer (CRC) screening, as it is the test your patients will use.
How many times have you recommended a CRC screening option and your patient either refused or never got around to doing the test? Now there`s PreGen-Plus, the non-invasive option your patients will choose. And with sensitivity four times (4x) that of FOBT and a demonstrated patient preference over FOBT and colonoscopy, PreGen-Plus makes sense.
PreGen-Plus is a safe, simple and non-invasive test to aid in the detection of colorectal cancer. Early detection of colorectal cancer is the key to saving lives and PreGen-Plus may represent an opportunity to save thousands of lives. Colorectal cancer screening has been shown to reduce mortality, and although several suitable and cost-effective tests are available, approximately 60% of the eligible population has never been screened. More importantly, only 37% of people with colorectal cancer are diagnosed in the earlier, more treatable stage.
EXAS
EXACT Sciences Corporation NASDAQ-NM
Umsatz 2001: 51.000$
Verlust: 23,4 Mio $
Umsatz 2002: 897.000$
Verlust: 29,9 Mio$
Umsatz 2003: 2,9 Mio$
Verlust: 28,3 Mio$
Umsatz 2004: 4,9 Mio$
Verlust: 18,5 Mio$
Quartal I 05:
Umsatz: 1,25 Mio$
Verlust: 4,5 Mio$
Zahlen für das 2. Quartal kommen am 26.7
MK: 59,8 Mio$ bei aktuellem Kurs 2,28$
Anteil Institutionelle: 49,5%
About EXACT Sciences
EXACT Sciences is an applied genomics company founded in 1995. The Company’s mission is to eradicate mortality from common cancers — starting with colorectal cancer — by applying advances in the field of genomics to facilitate the early detection of disease.
EXACT Sciences’ first target is colorectal cancer, the second leading cause of cancer deaths and the most deadly cancer among non-smoking men and women in the United States. This year, approximately 150,000 people will be diagnosed with colorectal cancer and almost 60,000 people will die from the disease. Of those diagnosed, nearly half are expected to die within five years, since most cancers are detected when the cancer is less treatable. For those whose cancer is detected at an earlier stage, the five-year survival rate can be greater than 90%. The American Cancer Society recommends that all Americans age 50 and older be screened regularly for colorectal cancer. Unfortunately, only a fraction of this population is screened for the disease, as currently available screening technologies are considered by many as either too invasive or inaccurate.
EXACT Sciences believes its non-invasive genomics-based technologies will revolutionize the early detection of colorectal cancer by increasing the number of people who are screened effectively and regularly for colorectal cancer.
PreGen-Plus™ can revolutionize your approach to colorectal cancer (CRC) screening, as it is the test your patients will use.
How many times have you recommended a CRC screening option and your patient either refused or never got around to doing the test? Now there`s PreGen-Plus, the non-invasive option your patients will choose. And with sensitivity four times (4x) that of FOBT and a demonstrated patient preference over FOBT and colonoscopy, PreGen-Plus makes sense.
PreGen-Plus is a safe, simple and non-invasive test to aid in the detection of colorectal cancer. Early detection of colorectal cancer is the key to saving lives and PreGen-Plus may represent an opportunity to save thousands of lives. Colorectal cancer screening has been shown to reduce mortality, and although several suitable and cost-effective tests are available, approximately 60% of the eligible population has never been screened. More importantly, only 37% of people with colorectal cancer are diagnosed in the earlier, more treatable stage.
07/26/2005 6:47AM EXAS: Q2 Earnings Call @ 08:30 ET Today
heute +7%
heute +7%
und wieder 7% auf 2,65 $
MARLBOROUGH, Mass., Jul 25, 2005 (BUSINESS WIRE) -- EXACT Sciences Corporation (NASDAQ: EXAS) today announced its financial results for the second quarter ending June 30, 2005.
For the quarter ending June 30, 2005, revenues totaled $0.6 million and included a non-recurring charge of $ 0.6 million related to the warrant extension described below, versus revenues of $1.2 million for the quarter ending June 30, 2004. These revenues mainly reflect the amortization of up-front license fee payments from Laboratory Corporation of America(R) Holdings (LabCorp(R)) and, to a lesser extent, royalties on LabCorp`s sales of PreGen-Plus(TM) (LabCorp`s colon cancer screening testing service), and sales of Effipure(TM) units to LabCorp.
The decrease in revenue for the three months ended June 30, 2005 as compared to the same period of the prior year was the result of a one-time, non-cash reduction in revenue of $0.6 million recorded in June 2005 in connection with the June 2005 extension of the expiration date of a warrant originally issued to LabCorp in June 2002.
Net loss for the quarter ending June 30, 2005 totaled $4.0 million, or $0.15 per share, compared to a net loss of $4.3 million, or $0.16 per share, for the same quarter last year.
During the quarter, 916 PreGen-Plus tests were accessioned by LabCorp. As of June 30, 2005, EXACT Sciences had approximately $40.5 million in cash, cash equivalents and short-term investments.
For the quarter ending June 30, 2005, revenues totaled $0.6 million and included a non-recurring charge of $ 0.6 million related to the warrant extension described below, versus revenues of $1.2 million for the quarter ending June 30, 2004. These revenues mainly reflect the amortization of up-front license fee payments from Laboratory Corporation of America(R) Holdings (LabCorp(R)) and, to a lesser extent, royalties on LabCorp`s sales of PreGen-Plus(TM) (LabCorp`s colon cancer screening testing service), and sales of Effipure(TM) units to LabCorp.
The decrease in revenue for the three months ended June 30, 2005 as compared to the same period of the prior year was the result of a one-time, non-cash reduction in revenue of $0.6 million recorded in June 2005 in connection with the June 2005 extension of the expiration date of a warrant originally issued to LabCorp in June 2002.
Net loss for the quarter ending June 30, 2005 totaled $4.0 million, or $0.15 per share, compared to a net loss of $4.3 million, or $0.16 per share, for the same quarter last year.
During the quarter, 916 PreGen-Plus tests were accessioned by LabCorp. As of June 30, 2005, EXACT Sciences had approximately $40.5 million in cash, cash equivalents and short-term investments.
hm, also fonds bauen hier derzeit mehr ab als auf
der chart sieht zwar wirklich nach boden aus auf dem niveau, aber mal schaun
der chart sieht zwar wirklich nach boden aus auf dem niveau, aber mal schaun
Trading Spotlight
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +5,46 | |
| +1,20 | |
| -0,04 | |
| +4,81 | |
| +4,35 | |
| +1,25 | |
| -2,67 | |
| +3,65 | |
| +5,04 | |
| +1,87 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 219 | ||
| 135 | ||
| 81 | ||
| 61 | ||
| 49 | ||
| 45 | ||
| 43 | ||
| 41 | ||
| 34 | ||
| 30 |
Exact Sciences - Biotechwert mit großer Hoffnung
